文献速递骨软组织肉瘤与黑色素瘤

新型磷酰胺类化合物在晚期软组织肉瘤III期研究中的命运

The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
PubMed 文献 · Eur J Cancer · 2017-08-23

本文回顾了多柔比星联合异环磷酰胺以及新型磷酰胺类化合物(evofosfamide和palifosfamide)在晚期软组织肉瘤中的III期随机试验结果。EORTC 62012显示联合组与单药组总生存无差异,但联合组缓解率和无进展生存期更优且毒性增加。TH CR-406/SARC021和PICASSO III中,联合组缓解率提高但毒性增加,总生存期和无进展生存期无获益;标准治疗组的中位总生存期较EORTC 62012有所改善。作者讨论了此类试验设计与实施的关键问题。

要点

  • EORTC 62012中多柔比星联合异环磷酰胺较单药未改善总生存,但缓解率和无进展生存期更优且毒性增加。
  • TH CR-406/SARC021和PICASSO III中,联合evofosfamide或palifosfamide组缓解率提高但毒性增加,总生存期和无进展生存期无获益。
  • 标准治疗多柔比星的中位总生存期在PICASSO III和TH CR-406/SARC021中较EORTC 62012有所改善。

核心结论

  • 三项随机III期研究显示,多柔比星联合异环磷酰胺或新型磷酰胺类化合物虽提高缓解率但增加毒性,未改善总生存期或无进展生存期。
  • 作者讨论了晚期软组织肉瘤临床试验设计与实施的关键问题,旨在为优化临床研究方法提供参考。

研究设计与样本

  • 本文为综述,汇总了EORTC 62012、TH CR-406/SARC021和PICASSO III三项随机III期临床试验的结果。
  • EORTC 62012比较多柔比星单药与多柔比星联合异环磷酰胺。
  • TH CR-406/SARC021比较多柔比星标准组与多柔比星联合evofosfamide。
  • PICASSO III比较多柔比星标准组与多柔比星联合palifosfamide。

主要发现

  • EORTC 62012中联合组与单药组总生存无差异,但联合组缓解率和无进展生存期更优,毒性增加。
  • TH CR-406/SARC021和PICASSO III中联合组缓解率提高但毒性更高,总生存期和无进展生存期无获益。
  • PICASSO III中标准治疗多柔比星的中位总生存期为16.9个月(95% CI 14.8-22.9)。
  • TH CR-406/SARC021中标准治疗多柔比星的中位总生存期为19.0个月(95% CI 16.2-22.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For decades, doxorubicin alone or in combination with ifosfamide has been used in advanced soft tissue sarcoma (STS). In 2014, a comparison of doxorubicin alone versus the combination with ifosfamide (in the randomised phase III EORTC 62012) showed no difference in overall survival (OS), but a difference in response and progression-free survival (PFS) were observed in favour of the combination but at the expense of increased toxicity. Newer fosfamides, with slightly different modes of action, and potentially less toxicity, namely evofosfamide and palifosfamide have recently been tested in randomised phase III clinical trials in STS. The TH CR-406/SARC021 (June 2017) and the PICASSO III (September 2016) studies compared doxorubicin, as the standard arm, to doxorubicin in combination with evofosfamide and palifosfamide, respectively. In both studies, the combination arm produced increased response rates but at the expense of higher toxicity. However, there was no difference in OS or PFS in favour of the combination. Importantly, the median OS of patients receiving standard of care, doxorubicin, in both studies appeared improved from 12.8 months (95.5% CI 10.5-14·III) in the EORTC 62012 to 16.9 months (95% CI 14.8 to 22.9) in PICASSO III and 19.0 months (95% CI 16.2-22.4) in TH CR-406/SARC021. The results of these three randomised phase III studies highlight several critical issues related to the design and conduct of such trials in STS. We discuss these issues aiming to contribute to the ongoing debate about the optimal approach to perform clinical research in STS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Constantinidou A, van der Graaf WTA. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer. 2017. PMID: 28841543. doi:10.1016/j.ejca.2017.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。